Mylan Inc. and Teva Pharmaceutical Industries Ltd. have launched tolterodine tartrate extended-release capsules, a medication for overactive bladder.


Mylan, Teva, generic versions, generic versions of Detrol LA, tolterodine tartrate extended-release capsules, authorized generic, Pfizer, overactive bladder


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan, Teva roll out Detrol LA generics

January 7th, 2014

NEW YORK – Mylan Inc. and Teva Pharmaceutical Industries Ltd. have launched tolterodine tartrate extended-release capsules, a medication for overactive bladder.

Both companies' products are generic versions of Detrol LA from Pfizer, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Mylan said Tuesday that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has released  tolterodine tartrate ER capsules in strengths of 2 mg and 4 mg.

Teva, which announced the launch of its product on Friday, said its tolterodine tartrate ER capsules, in 2-mg and 4-mg dosages, are the authorized generic of Detrol LA in the U.S. market.

Both companies reported that tolterodine tartrate ER capsules had annual U.S. sales of $571.5 million as of Sept. 30, 2013, according to data from IMS Health.

Advertisement